Alterity Therapeutics (ATHE) Shares Outstanding (2009 - 2026)

Alterity Therapeutics has reported Shares Outstanding (Entity) for 18 years, with the latest figure at $18.1 million in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) fell 96.6% year-over-year to $18.1 million in Q2 2026; TTM through Jun 2026 was $18.1 million, a 96.6% decrease from a year earlier, with the FY2026 full-year figure at $18.1 million, down 96.6% from the prior year.
• Shares Outstanding (Entity) was $18.1 million for Q2 2026 at Alterity Therapeutics, down from $533.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $533.1 million in Q2 2025, with the low at $18.1 million in Q2 2026.
• Average Shares Outstanding (Entity) over 5 years is $215.2 million, with a median of $201.9 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) soared 75.31% in 2025, then sank 96.6% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $200.6 million in 2022, then gained by 1.37% to $203.3 million in 2023, then plunged by 84.36% to $31.8 million in 2024, then surged by 1576.59% to $533.1 million in 2025, then tumbled by 96.6% to $18.1 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $18.1 million (Q2 2026), $533.1 million (Q2 2025), and $31.8 million (Q4 2024), per Business Quant data.